Trazodone
| Trazodone | |
|---|---|
| Salts [] | |
|---|---|
| Trazodone hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 371.90 g/mol [1] |
| Appearance | Crystals [1] |
| Melting point | 231-234 [1] |
| Boiling point | 528.5 [1] |
| Decomposition | When heated to decomposition it emits toxic fumes of /chlorides, hydrogen chloride and nitrogen oxides/. [1] |
| Solubility | 2.90e-01 g/L [1] |
| Predicted LogP | 2.8 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C19H22ClN5O |
| IUPAC name | 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one |
| SMILES | C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl |
| InChI | InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2 |
| InChIKey | PHLBKPHSAVXXEF-UHFFFAOYSA-N |
| CAS number | 19794-93-5 |
| UNII | YBK48BXK30 |
| PubChem CID | 5533 |
| Pharmacokinetics[] | |
|---|---|
| Onset | By mouth (IR): 1 hour (Time to peak concentrations)[3] |
| Elimination half-life | • Trazodone (immediate-release): 4–15 hours, • Trazodone (extended-release): 9–13 hours, • meta-Chlorophenylpiperazine: 3–16 hours[4] |
| Metabolism | Liver (CYP3A4, CYP2D6, CYP1A2?)[5] |
| Excretion | Urine: 70–75%, Feces: 21% |
| Routes of administration | By mouth |
| Dependence liability | Low[6] |
| Addiction liability | None |
| Toxicity [] | |
|---|---|
| LD50 | Mouse: - oral: 610 mg/kg - iv: 91 mg/kg - Intravenous: 96mg/kg Rat: - oral: 690 mg/kg - iv: 91 mg/kg - ip: 178 mg/kg [1] |
Trazodone (also known as Trazodon, Beneficat, Trazalon, Trazodil, Trazodona, Trazonil, Trittico, Desirel, Sideril or Trazodonum) is a serotonin agonist and serotonin reuptake inhibitor substance of the phenylpiperazine class.
Chemistry
Salts []
Stereochemistry []
Trazodone is achiral.
Druglikeness
Lipinski's rule of five
Trazodone matches Lipinski's rule of five.Reagents
There are currently 3 reagent-interactions on DrugsPRO
| Reagent | Color change | Description |
|---|---|---|
| Marquis | no color change | |
| Mecke | no color change | |
| Mandelin | no color change |
Pharmacology
ATC Classification
- nervous system (N)
- psychoanaleptics (N06)
- antidepressants (N06A)
- other antidepressants (N06AX)
- (N06AX05)
- trazodone (N06AX05)
MeSH Classification
- anti-anxiety agents (M0021771)
- antidepressive agents, second-generation (M0028000)
- selective serotonin reuptake inhibitors (M0556972)
Mechanism of action []
The mechanism of action of trazodone is not fully understood, however, it is known to inhibit the reuptake of serotonin and block both histamine and alpha-1-adrenergic receptors. Despite the fact that trazodone is frequently considered a selective serotonin reuptake inhibitor, several reports have shown that other mechanisms including antagonism at serotonin 5-HT1a, 5-HT1c, and 5-HT2 receptor subtypes may occur. The strongest antagonism of trazodone is reported to occur at the serotonin 5-HT21c receptors, preventing serotonin uptake. In addition to acting on serotonin receptors, trazodone has been shown to inhibit serotonin transporters. The antidepressant effects of trazodone result from the inhibition of receptor uptake, which normally decreases circulating neurotransmitters, contributing to depressive symptoms. [1]
Interactions []
Medical side effects []
183 side effects listed on drug labels in SIDER 4.1 (trazodone).
- Somnolence
- Dry mouth
- Dizziness
- Syncope
- Asthenia
- Fatigue
- Nervousness
- Tension
- Headache
- Constipation
- Vision blurred
- Weight decreased
- Back pain
- Hypotension
- Pain
- Ache
- Nightmare
- Abnormal dreams
- Visual impairment
- Confusional state
- Feeling abnormal
- Malaise
- Gastric disorder
- Diarrhoea
- Sinus congestion
- Tremor
- Tachycardia
- Agitation
- Weight increased
- Anger
- Hostility
- Disorientation
- Coordination abnormal
- Hyperhidrosis
- Discomfort
- Ill-defined disorder
- Memory impairment
- Ocular hyperaemia
- Cold sweat
- Sticky skin
- Libido decreased
- Disturbance in sexual arousal
- Libido increased
- Dyspnoea
- Hypertension
- Gait disturbance
- Balance disorder
- Dysgeusia
- Taste peculiar
- Amnesia
- Gastrooesophageal reflux disease
- Flushing
- Hypersensitivity
- Hypoaesthesia
- Numbness
- Speech disorder
- Speech impairment NOS
- Photophobia
- Eye pain
- Photosensitivity reaction
- Photosensitivity
- Muscle twitching
- Bladder pain
- Dry eye
- Deafness
- Hearing impaired
- Alopecia
- Haemolytic anaemia
- Anxiety
- Aphasia
- Apnoea
- Arrhythmia
- Ataxia
- Atrial fibrillation
- Cholestasis
- Diplopia
- Oedema
- Oesophageal achalasia
- Dermatitis
- Rash
- Eruption
- Hallucination
- Cardiac arrest
- Atrioventricular block
- Cardiac failure congestive
- Hirsutism
- Hyperbilirubinaemia
- Orthostatic hypotension
- Inappropriate antidiuretic hormone secretion
- Jaundice
- Leukocytosis
- Methaemoglobinaemia
- Myocardial infarction
- Acute coronary syndrome
- Nausea
- Palpitations
- Paraesthesia
- Tingling of extremity
- Priapism
- Pruritus
- Psoriasis
- Psychotic disorder
- Paranoia
- Salivary hypersecretion
- Cerebrovascular accident
- Shock
- Loss of consciousness
- Torsade de pointes
- Urinary incontinence
- Urticaria
- Vasodilation procedure
- Ventricular tachycardia
- Vertigo
- Vomiting
- Urinary retention
- Chills
- Stupor
- Depressed level of consciousness
- Amylase increased
- Ventricular extrasystoles
- Electrocardiogram QT prolonged
- Extrapyramidal disorder
- Nail discolouration
- Death
- Bradycardia
- Grand mal convulsion
- Surgery
- Tardive dyskinesia
- Insomnia
- Breast enlargement
- Abdominal pain
- Gastrointestinal pain
- Anaemia
- Decreased appetite
- Arthralgia
- Musculoskeletal discomfort
- Myalgia
- Chest pain
- Delusion
- Polyuria
- Body temperature increased
- Flatulence
- Angle closure glaucoma
- Haematuria
- Hyponatraemia
- Incontinence
- Eye pruritus
- Jaundice cholestatic
- Lethargy
- Miosis
- Nasal congestion
- Night sweats
- Sensory loss
- Orgasm abnormal
- Completed suicide
- Suicide attempt
- Tinnitus
- Pollakiuria
- Micturition urgency
- Vasculitis
- Poor quality sleep
- Sinus bradycardia
- Hypokinesia
- Migraine
- Menstruation irregular
- Musculoskeletal stiffness
- Increased appetite
- Dysarthria
- Sedation
- Disturbance in attention
- Mental disability
- Hypomania
- Erectile dysfunction
- Akathisia
- Retrograde ejaculation
- Dyskinesia
- Mean arterial pressure
- Sexual dysfunction
- Electrocardiogram PR prolongation
- Serotonin syndrome
- Haemorrhagic disorder
- Abdominal discomfort
- Leukocytoclastic vasculitis
Indications
- Agitation
- Anxiety
- Bradypsychic response
- Cerebration impaired
- Decreased interest
- Depressive disorder
- Drug interaction
- Dysphoria
- Fatigability
- Feeling guilty
- Major depression
- Major depressive disorder, single episode
- Sexual dysfunction
- Suicidal ideation
Subjective effects []
Experience reports
Legal status []
- Australia: Trazodone is a Schedule 4.
- Brazil: Trazodone is a C1.[7]
- Canada: Trazodone is Prescription only.
- United Kingdom: Trazodone is Prescription only.
- United States: Trazodone is Prescription only.
- Other: Trazodone is a Rx-only.
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 5533, Trazodone. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5533
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Trazodone. UNII: YBK48BXK30. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/YBK48BXK30
MicroMedex DrugPoints – Trazodone. Pharmacy Choice. http://www.pharmacychoice.com/mdx/drugpoint.cfm?docID=622860&letter=T&type=Generic%20Name
Schatzberg AF, Nemeroff CB. The American Psychiatric Association Publishing Textbook of Psychopharmacology. American Psychiatric Pub. 2017. https://books.google.com/books?id=KfHEDgAAQBAJ&pg=PA460
Lemke TL, Williams DA. Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. 2012. https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA615
Hubbard JR, Martin PR. Substance Abuse in the Mentally and Physically Disabled. CRC Press. 2001. https://books.google.com/books?id=MY1kFYk98mQC&pg=PA26
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 10:56:30 |
| drugspro | ok | 2026-11-20 10:56:26 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 10:56:26 |
| gsrs | ok | 2026-11-20 10:56:27 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014794) | 2026-11-20 10:56:26 |
| kegg | ok | 2026-11-20 10:56:28 |
| pubchem | ok | 2026-11-20 10:56:26 |
| ok | 2026-11-20 10:56:26 | |
| sider | ok | 2026-11-20 10:56:27 |
| structure | ok | 2026-11-20 10:56:26 |
| wikipedia | ok | 2026-11-20 10:56:27 |